Please note: This event has been postponed until September 10th

“Trauma is not what happens to us, but what we hold inside in the absence of an empathetic witness” -Peter Levine I

n this era of trauma informed care and psychedelic healing, the trinity of mindfulness, somatic embodiment, and psychedelic journeys serve as three powerful and often essential pillars for healing.

In this fireside chat, Salimeh Tabrizi, founding member of the PAC, plant medicine facilitator and clinical counselor and David Field, somatic experiencing and trauma integration therapist discuss and explore the ways in which somatic experiencing and psychedelic-assisted therapy work, as well as near death experiences, together help individuals and couples access deeper healing, connection and resilience; the kind that is embodied and fully felt in the body and spirit as well as the mind.

Join us for an honest, grounded conversation about somatic experiencing, trauma integration healing and specific practices for individuals, couples and communities.

The webinar includes a structured Q&A session, at the end, to deepen the discussion.

Please note the early start time of 10:00am PT/1:00pm ET

*Please note this webinar is 1 hr and will begin at 3:00pm PT/6:00pm ET

Something shifted in Ottawa this week.

On June 16th, Conservative MP Corey Tochor introduced Bill C-286 — Thomas's Law — legislation that would allow Canadian physicians to prescribe psilocybin directly to patients, bypassing the federal approval process that has left thousands of people without access to a treatment that research shows can be life-changing.

The bill bears the name of Thomas Hartle — a Saskatchewan father who, in 2020, became the first Canadian to receive a legal psilocybin exemption while battling stage IV colon cancer. When his cancer progressed, his renewal requests sat unanswered for months. A dying man spent his final years fighting bureaucratic silence just to keep a treatment that was helping him. Thomas passed away in 2024. This bill is his legacy.

Since January 2022, Health Canada has issued only 354 psilocybin authorizations through the Special Access Program — with approval rates now sitting at roughly 30%. For patients living with PTSD, treatment-resistant depression, addiction, and end-of-life distress, that's not a safety net. It's a wall.

Join us for a live conversation with the MP who decided to do something about it.

Dr. Pamela Kryskow — physician, researcher, and PAC Board Chair — sits down with MP Tochor to cover:

• What brought him to this bill — the conversations, the cases, and the moment a Conservative MP decided psilocybin access was worth fighting for
• What Canadians told him — the stories from patients, families, and clinicians that shaped the legislation
• How a private member's bill actually works — a plain-language walkthrough of the parliamentary process, from tabling to committee to vote
• What it needs to pass — the political landscape, the numbers, and what has to happen next
• What you can do right now — concrete ways Canadians can support Bill C-286 and help it move forward

Whatever your background — patient, practitioner, advocate, or curious citizen — this is a conversation that matters. A cross-party moment in Canadian psychedelic medicine policy is rare. This is one.

Join us for a evidence-informed overview of 5-MeO-DMT, a short-acting psychedelic tryptamine gaining attention for its profound, rapidly emerging non-ordinary states of consciousness and potential therapeutic applications in mood and trauma-related conditions.

In this webinar, we will explore current science on its pharmacology, subjective effects, and emerging clinical research, while also addressing safety, ethics, and best practices for responsible, trauma-informed use in modern care and ceremonial contexts.